Загрузка...
Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer
Intravesical BCG is active against non-muscle invasive bladder cancer (NMIBC), but bladder cancer will recur and even progress in a significant number of patients. To improve the response rate, N-803, an IL-15 superagonist was administered in combination with BCG. To evaluate the safety and efficacy...
Сохранить в:
| Опубликовано в: : | Oncoimmunology |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Taylor & Francis
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8096327/ https://ncbi.nlm.nih.gov/pubmed/33996264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1912885 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|